{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T01:48:16Z","timestamp":1781920096403,"version":"3.54.5"},"reference-count":31,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2024,3,22]],"date-time":"2024-03-22T00:00:00Z","timestamp":1711065600000},"content-version":"unspecified","delay-in-days":21,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"National High Level Hospital Clinical Research Funding","award":["2022-PUMCH-B-013"],"award-info":[{"award-number":["2022-PUMCH-B-013"]}]},{"name":"National High Level Hospital Clinical Research Funding","award":["2022-PUMCH-D-009"],"award-info":[{"award-number":["2022-PUMCH-D-009"]}]},{"DOI":"10.13039\/501100009592","name":"Beijing Municipal Science & Technology Commission","doi-asserted-by":"crossref","award":["Z201100005520022"],"award-info":[{"award-number":["Z201100005520022"]}],"id":[{"id":"10.13039\/501100009592","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100009592","name":"Beijing Municipal Science & Technology Commission","doi-asserted-by":"crossref","award":["Z201100005520023"],"award-info":[{"award-number":["Z201100005520023"]}],"id":[{"id":"10.13039\/501100009592","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100009592","name":"Beijing Municipal Science & Technology Commission","doi-asserted-by":"crossref","award":["Z201100005520025"],"award-info":[{"award-number":["Z201100005520025"]}],"id":[{"id":"10.13039\/501100009592","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100009592","name":"Beijing Municipal Science & Technology Commission","doi-asserted-by":"crossref","award":["Z201100005520026"],"award-info":[{"award-number":["Z201100005520026"]}],"id":[{"id":"10.13039\/501100009592","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100009592","name":"Beijing Municipal Science & Technology Commission","doi-asserted-by":"crossref","award":["Z201100005520027"],"award-info":[{"award-number":["Z201100005520027"]}],"id":[{"id":"10.13039\/501100009592","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the Chinese National Key Technology R&D Program, Ministry of Science and Technology","award":["2021YFC2501300"],"award-info":[{"award-number":["2021YFC2501300"]}]},{"name":"CAMS Innovation Fund for Medical Sciences","award":["2021-I2M-1-005"],"award-info":[{"award-number":["2021-I2M-1-005"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2024,2,22]]},"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To investigate the treatment efficacy and safety of baricitinib in patients with refractory Takayasu arteritis (TAK).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We performed a prospective cohort study in which baricitinib 4\u2009mg daily was prescribed to patients with refractory TAK, combined with oral glucocorticoids (GCs).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>10 patients with refractory TAK were enrolled with a median age of 28 (IQR=22\u201337) years, median disease duration of 50 (IQR=24\u201365) months. The median dose of GCs was 10 (IQR=8.1\u201322.5)\u2009mg prednisone or equivalence dosage at baseline. At 6\u2009months of baricitinib treatment, 6\/10 (60%) patients had an overall treatment response. During an average follow-up of 15.3 (range 4\u201331) months, 4\/10 (40%) patients maintained overall treatment response. 8\/10 (80%) patients tapered or maintained the same dose of GCs with no change of the combined classical synthetic disease-modifying antirheumatic drugs. Two patients discontinued GCs at 18 and 24 months and were in continuous remission till the end of the study. One patient withdrew baricitinib due to liver dysfunction.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Baricitinib 4\u2009mg daily is effective for refractory TAK and is well tolerated.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/rmdopen-2023-003985","type":"journal-article","created":{"date-parts":[[2024,3,22]],"date-time":"2024-03-22T13:05:44Z","timestamp":1711112744000},"page":"e003985","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":10,"title":["Baricitinib for refractory Takayasu arteritis: a prospective cohort study in a tertiary referral centre"],"prefix":"10.1136","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6580-4419","authenticated-orcid":false,"given":"Ziyue","family":"Zhou","sequence":"first","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, National Clinical Research Center for Dermatologic and Immunologic Diseases, the Ministry of Education Key Laboratory, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Dongcheng-qu, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenglong","family":"Fang","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, National Clinical Research Center for Dermatologic and Immunologic Diseases, the Ministry of Education Key Laboratory, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Dongcheng-qu, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Rheumatology, The Third People's Hospital of Yunnan Province, Kunming, Yunnan province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2504-1629","authenticated-orcid":false,"given":"Jing","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, National Clinical Research Center for Dermatologic and Immunologic Diseases, the Ministry of Education Key Laboratory, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Dongcheng-qu, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunjiao","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, National Clinical Research Center for Dermatologic and Immunologic Diseases, the Ministry of Education Key Laboratory, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Dongcheng-qu, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, National Clinical Research Center for Dermatologic and Immunologic Diseases, the Ministry of Education Key Laboratory, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Dongcheng-qu, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shangyi","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, National Clinical Research Center for Dermatologic and Immunologic Diseases, the Ministry of Education Key Laboratory, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Dongcheng-qu, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofeng","family":"Zeng","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, National Clinical Research Center for Dermatologic and Immunologic Diseases, the Ministry of Education Key Laboratory, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Dongcheng-qu, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1511-7952","authenticated-orcid":false,"given":"Xinping","family":"Tian","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, National Clinical Research Center for Dermatologic and Immunologic Diseases, the Ministry of Education Key Laboratory, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Dongcheng-qu, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,3,22]]},"reference":[{"key":"2025090312530206000_10.1.e003985.1","doi-asserted-by":"crossref","first-page":"22","DOI":"10.2478\/rir-2023-0004","article-title":"Clinical and vascular features of stroke in Takayasu\u2019s arteritis: A 24-year retrospective study","volume":"4","author":"Zhang","year":"2023","journal-title":"Rheumatol Immunol Res"},{"key":"2025090312530206000_10.1.e003985.2","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1007\/s00296-021-04958-5","article-title":"Corticosteroid monotherapy for the management of Takayasu arteritis-a systematic review and meta-analysis","volume":"41","author":"Misra","year":"2021","journal-title":"Rheumatol Int"},{"key":"2025090312530206000_10.1.e003985.3","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215672"},{"key":"2025090312530206000_10.1.e003985.4","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-021-00726-8"},{"key":"2025090312530206000_10.1.e003985.5","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1197342","article-title":"Changes in the molecular profiles of large-vessel vasculitis treated with biological disease-modifying anti-rheumatic drugs and Janus kinase inhibitors","volume":"14","author":"Matsumoto","year":"2023","journal-title":"Front Immunol"},{"key":"2025090312530206000_10.1.e003985.6","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1174249","article-title":"Arterial wall fibrosis in Takayasu arteritis and its potential for therapeutic modulation","volume":"14","author":"Misra","year":"2023","journal-title":"Front Immunol"},{"key":"2025090312530206000_10.1.e003985.7","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220832"},{"key":"2025090312530206000_10.1.e003985.8","doi-asserted-by":"crossref","first-page":"e95","DOI":"10.1093\/rheumatology\/keaa281","article-title":"Tofacitinib in patients with refractory Takayasu\u2019s arteritis","volume":"59","author":"Li","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"2025090312530206000_10.1.e003985.9","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2022.152018","article-title":"Efficacy and safety of tofacitinib versus Leflunomide with glucocorticoids treatment in Takayasu arteritis: A prospective study","volume":"55","author":"Wang","year":"2022","journal-title":"Semin Arthritis Rheum"},{"key":"2025090312530206000_10.1.e003985.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2013.05.024"},{"key":"2025090312530206000_10.1.e003985.11","doi-asserted-by":"crossref","first-page":"188","DOI":"10.2478\/rir-2023-0028","article-title":"Advances and challenges in management of large vessel vasculitis","volume":"4","author":"Chu","year":"2023","journal-title":"Rheumatol Immunol Res"},{"key":"2025090312530206000_10.1.e003985.12","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221961"},{"key":"2025090312530206000_10.1.e003985.13","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1002\/art.1780330811","article-title":"The American college of rheumatology 1990 criteria for the classification of Takayasu arteritis","volume":"33","author":"Arend","year":"1990","journal-title":"Arthritis Rheum"},{"key":"2025090312530206000_10.1.e003985.14","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2478\/rir-2021-0014","article-title":"Clinical characteristics of adult patients with systemic vasculitis: data of 1348 patients from a single center","volume":"2","author":"Li","year":"2021","journal-title":"Rheumatol Immunol Res"},{"key":"2025090312530206000_10.1.e003985.15","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-120-11-199406010-00004"},{"key":"2025090312530206000_10.1.e003985.16","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-5273(96)02813-6"},{"key":"2025090312530206000_10.1.e003985.17","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1002\/art.42496","article-title":"Comparative efficacy of Secukinumab versus tumor necrosis factor inhibitors for the treatment of Takayasu arteritis","volume":"75","author":"Tian","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"2025090312530206000_10.1.e003985.18","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.117.030423"},{"key":"2025090312530206000_10.1.e003985.19","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216900"},{"key":"2025090312530206000_10.1.e003985.20","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220873"},{"key":"2025090312530206000_10.1.e003985.21","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-36825-y","article-title":"Serum levels of fibroblast growth Factor-2 distinguish Takayasu arteritis from giant cell arteritis independent of age at diagnosis","volume":"9","author":"Fukui","year":"2019","journal-title":"Sci Rep"},{"key":"2025090312530206000_10.1.e003985.22","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s00296-016-3648-3","article-title":"Single nucleotide Polymorphisms of Il12B are associated with Takayasu arteritis in Chinese Han population","volume":"37","author":"Wen","year":"2017","journal-title":"Rheumatol Int"},{"key":"2025090312530206000_10.1.e003985.23","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-93213-9","article-title":"A susceptibility locus in the Il12B but not Lilra3 region is associated with vascular damage in Takayasu arteritis","volume":"11","author":"Kadoba","year":"2021","journal-title":"Sci Rep"},{"key":"2025090312530206000_10.1.e003985.24","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-213488"},{"key":"2025090312530206000_10.1.e003985.25","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-017-1408-8","article-title":"A novel susceptibility locus in the Il12B region is associated with the pathophysiology of Takayasu arteritis through IL-12P40 and IL-12P70 production","volume":"19","author":"Nakajima","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"2025090312530206000_10.1.e003985.26","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1093\/rheumatology\/kez580","article-title":"A case of Takayasu arteritis complicated by refractory ulcerative colitis successfully treated with tofacitinib","volume":"59","author":"Sato","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"2025090312530206000_10.1.e003985.27","doi-asserted-by":"crossref","first-page":"e389","DOI":"10.1093\/rheumatology\/keab541","article-title":"Efficacy of Baricitinib for refractory large-vessel vasculitis","volume":"60","author":"R\u00e9gent","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"2025090312530206000_10.1.e003985.28","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1080\/14740338.2020.1799975","article-title":"A real-world Disproportionality analysis of FDA adverse event reporting system (FAERS) events for Baricitinib","volume":"19","author":"Peng","year":"2020","journal-title":"Expert Opin Drug Saf"},{"key":"2025090312530206000_10.1.e003985.29","unstructured":"Zhao X , Zhang C , An Y , et al . Research on liver damage caused by the treatment of rheumatoid arthritis with novel biological agents or targeted agents"},{"key":"2025090312530206000_10.1.e003985.30","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1080\/14740338.2020.1743263","article-title":"The safety of Baricitinib in patients with rheumatoid arthritis","volume":"19","author":"Honda","year":"2020","journal-title":"Expert Opin Drug Saf"},{"key":"2025090312530206000_10.1.e003985.31","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2109927"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2023-003985","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T19:53:11Z","timestamp":1756929191000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2023-003985"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,3,22]]},"published-print":{"date-parts":[[2024,3]]}},"alternative-id":["10.1136\/rmdopen-2023-003985"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2023-003985","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3]]}}}